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ABSTRACT 
Biomarkers of Coagulation and Fibrinolysis in Primary Graft Dysfunction in Lung 
Transplant Recipients 
Nancy A. Robinson 
Jason D. Christie, Supervisor, M.D., M.S. 
 
 
Primary graft dysfunction (PGD) is a severe acute lung injury syndrome 
following lung transplantation.1-3  In the lung transplant clinical and research community, 
PGD has received much attention as a leading cause of morbidity and mortality and is the 
primary cause of almost half of lung transplant deaths in the first 30 days. 
There has been increasing recognition that impaired fibrinolysis plays a role in 
pathogenesis of acute lung injury.  Furthermore, inherent donor and recipient 
characteristics may play an important role in determining risk of PGD in laboratory 
models and clinical studies, suggesting that this variation may partially be due to 
differing susceptibility to lung injury in recipients and donors.  
The focus of this thesis was the role of biomarkers in the coagulation and 
fibrinolytic pathways in the development of PGD in human lung transplant recipients. 
Plasma levels of Protein C and Plasminogen Activator Inhibitor “PAI-1” pre-transplant, 
immediate post-transplant, 24, 48, and 72 hours post-transplant were measured in 131 
lung transplant recipients.  The primary outcome was PGD, defined as International 
Society of Heart and Lung Transplantation (ISHLT) Working Group definition of PGD, 
Grade 3. Potential confounding effects of clinical variables were also evaluated using 
logistic regression models. 
15% of subjects were identified as PGD, Grade 3.  Lower levels of Protein C and 
higher levels of PAI -1 were associated with the PGD cases.  Recipient’s diagnosis and 
procedure type as well as the administration of blood products within 24 hours post 
 ix 
transplant and Pulmonary Arterial Systolic Pressure (PASP) were all determined to be 
statistically different between the PGD and Non-PGD groups.   The association of both, 
Protein C and PAI-1, with PGD were independent of all potential confounders. 
This research provides evidence that decreased levels of Protein-C and increased 
levels of PAI-1 in circulating plasma contribute to the development of PGD in lung 
transplant patients. The goal of this research was to present insight into the mechanisms 
of progression to PGD, to aid in potential prediction of PGD, and to put forward 
justification for novel therapeutics (Protein C), aimed at preventing PGD prior to full 
onset or death. 
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1. SPECIFIC AIMS 
1.1. Specific Aim 1: 
Determine the relationship of Protein C with PGD. 
1.2. Specific Aim 2: 
Determine the relationship of PAI -1 with PGD. 
1.3. Specific Aim 3:  
Determine the relationship of potential confounder variables with biomarker 
levels and the outcome, PGD. 
2. INTRODUCTION 
2.1. Primary Graft Dysfunction  
PGD is a severe form of ARDS specific to lung transplant patients that follows 
the sequence of events inherent in the lung transplantation process, beginning with the 
brain death of the donor, pulmonary ischemia, preservation of donor tissue, 
transplantation, and reperfusion of donor tissue in the recipient.4;5 The more severe forms 
of PGD result in profound hypoxemia, and have a major impact on outcomes following 
lung transplantation, markedly increasing early mortality, length of hospitalization, length 
of time requiring mechanical ventilation, and overall cost.1;6 Thus, any intervention 
aimed at prevention and diagnosis could dramatically improve clinical and economic 
outcomes following lung transplantation.  
The lung transplant procedure begins with selection of an appropriate candidate 
recipient. Patients who are eligible for lung transplantation include those with advanced 
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diseases of the pulmonary parenchyma, airways or blood vessels that have led them to 
have a high expectation of mortality within the next five years.5 Examples of advanced 
lung diseases requiring lung transplantation include: emphysema, cystic fibrosis, 
sarcoidosis, idiopathic pulmonary arterial hypertension (IPAH or PPH), and idiopathic 
pulmonary fibrosis (IPF). 
Despite numerous recent advances in organ preservation,7;8 surgical technique, 
and preoperative care, it is clear that PGD is responsible for significant morbidity and 
mortality following lung transplantation, see Figure 1, Survival Estimates, Christie, Chest 
2005.9 The most severe forms of PGD have an incidence of 10-25% and are associated 
with a 30-day mortality of 50-75%.1;6;10 According to the most recent ISHLT registry 
report, PGD accounts for the majority of early mortality after lung transplantation.9  In 
addition, survivors of PGD have a protracted recovery, with prolonged critical illness and 
a mortality deficit extending beyond the first year.9;11 Thus, any intervention that 
successfully identifies/classify PGD following lung transplant, would dramatically 
improve morbidity and mortality rates within future lung transplant recipients. 
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Figure 1: PGD Survival Estimates 
2.2. Definition of PGD 
The list of synonyms for PGD includes ischemia-reperfusion injury, 
reimplantation response, reimplantation edema, reperfusion edema, non-cardiogenic 
pulmonary edema, early graft dysfunction, primary graft dysfunction, primary graft 
failure, and post-transplant acute respiratory distress syndrome (ARDS) or acute lung 
injury (ALI).3;12 Recently, the defining criteria for PGD were standardized. The 
International Society of Heart and Lung Transplantation (ISHLT) Working Group on 
Primary Lung Graft Dysfunction was formed at the suggestion of the ISHLT Pulmonary 
Council in 2003, with Dr. Christie as chair. A major goal of this group was to standardize 
consensus defining criteria to facilitate future studies of PGD.1-3;13;14 The reports of this 
group are employed in the proposed research for defining PGD and PGD grade (Table 1). 
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Table 1: ISHLT Grading of PGD 
GRADE PaO2/FiO2 Infiltrates 
0 >300 Absent 
1 >300 Present 
2 200-300 Present 
3 <200 Present 
 
 
 
 
For this research, PGD was defined as the presence of diffuse radiographic 
infiltrates in the allograft during first the 72 hours postoperative (see Figure 2 ); P/F ratio 
< 200 at 72 hours; ventilator dependence beyond the first 5 days directly attributable to 
allograft dysfunction; the absence of other identifiable causes for poor allograft function; 
and in the event of death in the first 6 days postoperative, histologic evidence of diffuse 
alveolar damage (DAD) after meeting all other criteria for PGD.1 
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Figure 2: Example X-Ray of Diffuse Radiographic Infiltrates vs. Normal X-Ray 
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2.3. The Complex Pathophysiology of PGD 
PGD results from a series of events correlating with lung transplant, including 
factors such as brain death of the donor, pulmonary ischemia of donor, preservation of 
donor tissue; as well as other factors including transplantation of the lung and re-
oxygenation of the donor lung into the recipient.15 Many inter-related pathophysiological 
mechanisms contribute to the development of PGD. In general PGD is characterized by 
patchy pulmonary infiltrates, widening of the alveolar-arterial Po2 gradient, diminished 
lung compliance, and pathologic findings of diffuse alveolar damage.2;3;11;13 Oxygen 
radicals, inflammatory cytokines, coagulation product and complement activation, 
fibrinolyisis, platelet and immune cell activation, proteases, leukotrienes and eicosanoids 
are all thought to play a role in PGD.3;12;13;16-24 In addition, factors specific to fibrosis and 
repair may be important in the later stages of PGD.10;11  
The stages of injury during the transplant process, including removal of the donor 
lung and transplant into recipient can be categorized with some pathways being active in 
the earlier and others present in the later stages. Some of the earlier stages of injury are 
characterized by ischemia and reperfusion of the donor lung, as well as the generation of 
reactive oxygen species.  
Injury during the early stages of PGD are characterized by oxidative stress 
mechanisms, while later stages of injury are characteristic of inflammatory response, 
including an increase of production/presence of adhesion molecules on pulmonary cells 
and macrophages. In the later phase, the production of cytokines and increased 
concentration of neutrophils in the lungs produced by macrophages stimulated by 
increased levels of powerful vascocontrictors and enothelins are thought to be a major 
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source of injury.25;26 Another characteristic of the later stages of injury, after reperfusate, 
is thought to be the release of interferon gamma by lymphocytes.27 
In response to the transplant process an increase of adhesion molecules are seen 
on pulmonary macrophages and pulmonary cells. The end result being activation of 
recipient neutrophils and T lymphocytes in reaction to the release of proinflammatory 
cytokines from the donor lung.12 
In a cascade initiated by the release of platelet activating factor in response to 
cellular injury, leukocytes, activated by platelet activating factor receptor stimulates 
platelet aggregation, cytokine release and the expression of cell adhesion molecules.28;29 
Various immune cells, following reperfusion, further play a role in lung injury via 
activation of the complement system resulting in additional smooth muscle contraction, 
up regulation of vascular permeability, and the release of cytotoxic granules.30  
Evidence currently exists demonstrating that before and after reperfusion, 
macrophages, lymphocytes, and neutrophils all play a role in PGD. The release of 
cytokines and other mediators and the fact that the transplanted lung is scouted by and 
filled with lymphocytes and neutrophils.27 In response to the oxidative stress that occurs, 
cytokines and procoagulant agents are activated by alveolar macrophages in response to 
the oxidative stress.31;32 Reactive oxygen species “ROS” can regulate PAI-1 and 
inflammation.  In several studies higher levels of ROS have previously been associated 
with increased levels of PAI-1. ROS has also been implicated to play a regulatory role in 
the regulation of coagulation and fibrinolysis.33  Of the above mechanisms, the activation 
of procoagulant agents is thought to be very important in not only the development but 
also the outcome of lung transplant patients that develop PGD.  
  
8
Although there may be numerous potential mechanistic pathways and biomarkers 
that presents as PGD susceptibility pathways, this research focused on the role of the 
coagulation and fibrinolysis regulatory pathways in the development and outcomes of 
PGD.   See section below entitled “Role of Coagulation and Fibrinolysis in the 
Pathogenesis of PGD”.    
2.4. Role of Coagulation/Fibrinolysis in the Pathogenesis of PGD 
Malfunctions in both the coagulation and fibrinolysis pathways have been 
associated with the development and progression of ARDS, as well as PGD. In previous 
research it was concluded that ARDS patient’s alveolar lining fluids are predisposed to 
alveolar fibrin depositon, due to both enhanced coagulation and depressed fibrinolysis, 
see Figure 3, Inflammatory/Coagulant Activity, Mathay, NEJM, 2001.34  
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Figure 3: Inflammatory/Coagulant Activity 
 
Previous research with ARDS patients reported a higher than normal tissue factor 
levels, as well as significantly lower platelet counts as opposed to the other study subjects 
(patients at risk for but not developing ARDS and patients without ARDS) and control 
subjects (normal healthy volunteers).35  The outcomes of this previous research with 
ARDS patients support the hypothesis of my research, the coagulation pathway, 
specifically tissue factor activation and platelet consumption is associated with the 
progression of lung dysfunction.  
Additional evidence in support of my research is provided by the investigation of 
autoamplification by activated complexes with reduction and or inhibition of coagulation 
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inhibitors ability to produce fibrinolysis, ultimately leading to acute lung injury pattern36; 
as well as the reported overexpression of fibrinolytic activity by activated protein C and 
the suppression of thrombin –dependent inactivation of PAI-1.37  Although these research 
studies were conducted in ARDS patients, a less specific and less severe but similar 
syndrome, they provide sufficient evidence to support the investigation of this research in 
the PGD population. Protein C and PAI-1 are important in PGD research because Protein 
C inhibits the coagulation pathway and PAI-1 inhibits fibrinolysis, two mechanisms that 
are thought to be interrupted, and as such causes an imbalance of specific biomarkers  in 
PGD patients. 
2.5. Role of Protein C in the Pathogenesis of PGD  
Protein C is an essential component in the regulation of the mechanism by which 
the body regulates bleeding, causing it to stop (haemostasis). Haemostatis consists of 
several different components, including platelets, blood vessels, inhibitors in the 
fibrinolytic pathway, coagulation factors and their inhibitors. In addition heaemostatis, 
occurs in several stages including primary haemostasis (platelets bind to collagen), 
secondary haemostatis (onset of coagulation and formation of fibrin clot) and fibrinolysis 
(degradation of fibrin clots). Activated Protein C “APC” it is part of the mechanism for 
controlling the coagulation of blood in response to injury, see Figure 4. Protein C is made 
in the liver. It is a vitamin K dependent plasma protein, and is normally present in small 
quantities in human plasma. Protein C circulates in the blood in its inactive, zymogen 
form, and is converted 'on site' and 'on demand' during coagulation activation into the 
enzyme activated protein C (APC) with the help of a substance called thrombomodulin. 
Protein C is converted into an active protease by Thrombin after it’s bound to 
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thrombomodulin. The activated form of Protein C, APC, along with several cofactors and 
phospholipids degrades important coagulation factors, Factor Va and Factor VIIIS. APC 
exhibits both anti-inflammatory and anti-apoptic activities as well as a source of 
antithrombotic activity. APC has a number of controlling effects on the coagulation 
cascade. Such effects include:  
 
• Regulation of haemostasis through a negative feedback on thrombin generation  
• Beneficial influence on the inflammation process  
• Indirect pro-fibrinolytic effects  
 
Upon vascular injury, the thrombomodulin receptor on the cell’s surface is bound 
by thrombin, causing thrombin to cease procoagulant properties. While thrombin looses 
its procagulant properties in this cascade, APC becomes highly activated by thrombin 
binding to the thrombomodulin receptor. After binding of the thrombomodulin receptor, 
Protein C functions as a circulating anticoagulant, which degrades and inactivates the 
phospholipid –bound factors Va and VIIIa, see Figure 4 (Protein C; 
www.en.wikipedia.org)38;39.  Effectively down regulating, the coagulation cascade and 
limiting clot formation to sites of vascular injury. 
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Figure 4: Protein C Pathway 
 
The coagulation cascade is a complex chain of events which leads to clotting 
when injury occurs; see Figure 5, Coagulation Cascade - Activated Protein C, National 
Initiative in Sepsis Education (NISE). It includes the process by which a clot dissolves 
after healing. Normally, the substances involved in coagulation maintain a balance of clot 
formation and dissolution. If this balance is upset, however, a range of diseases can 
occur, many of which are life-threatening and often fatal. For example, excessive clotting 
can cause blood vessels to become blocked. This, in turn, can cause the tissues they 
supply with blood to become damaged or even die. Alternatively, if the blood can not clot 
properly excessive bleeding may occur. A deficiency in protein C results in defective 
control of the clotting mechanism, which has been shown to be associated with PGD. 
Recent work by Bernard et el reported on the therapeutic effect of activated Protein C in 
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patients with severe sepsis.40 In addition it was previously reported that administration of 
human recombinant protein C (Xigris) as a possible means of restoring dysfunction of the  
protein C pathway.41;42 The focus of this research is the levels of Protein C post lung 
transplant as compared to that of normal Protein C levels to better understand the 
correlation of its inhibition of the coagulation pathway and how it effects the onset and 
progression of PGD in Lung Transplant patients.  
 
Figure 5: Coagulation Pathway 
 
 
The hypothesis of this thesis is supported by previous research conducted by 
Ware et al, in which lower levels of Protein C were associated with the worst clinical 
outcomes, increased deaths and organ failure of non pulmonary organs, as well as 
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number of days on a ventilator in patients with ARDS 43;44.   Ware et al further identified 
protein C and plasminogen activator inhibitor-1, as two of several biologic markers 
consistently identified as independent predictors of death in ARDS45. 
 
2.6. Role of Plasminogen Activator Inhibitor-1 (PAI-1) in the 
Pathogenesis of PGD 
Plasminogen activator inhibitor-1 (PAI-1) is an important mediator in determining 
fibrogenic/fibrolytic coagulation balance, see Figure 6 (Fibrinolysis,Walker & 
Nesheim,1999;www.en.wikipedia.org)39.  
 
 
Figure 6: Fibrinolysis 
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The main function of PAI-1 is to decrease/ inhibit fibrinolysis, which leads to 
fibrin accumulation. An elevated plasma PAI-1 concentration has been identified as a risk 
factor for the development of myocardial infarction, a factor associated with PGD46;47 , 
see Figure 7 (Complex Coagulation Cascade, Ware, NEJM, 2000).38;39;48   
A role for PAI-1 as a key mediator in the pathobiology of PGD has been 
suggested by several studies. Graft failure manifests histopathologically in its earliest 
stages in an exudative phase characterized by intraalveolar fibrin and hyaline membranes. 
Those patients that fail to resolve during this phase subsequently demonstrate ineffective 
repair with extensive fibroproliferation and derangement of alveolar gas transport 
architecture.46;47 This observation suggests a potential link between a persistent 
fibrogenic coagulation balance and the progression to fibrosis. This supposition is 
supported by animal models of bleomycin-induced fibrosis in which PAI-1 genetic 
deletion resulted in reduced fibrosis, thereby indicating not only that fibrogenic 
coagulation balance is linked to fibroproliferation, but that PAI-1 is a key mediator of this 
pathophysiologic set of events.38;39;48;49 46;47 
Immediately with tissue damage and formation of a clot, the fibrinolytic systems 
through several pathways interrupt clot formation. The principal pathway is through the 
intraclot formation of plasmin from plasminogen by tissue plasminogen activator (t-
PA),which is a serine protease. t-PA is released from endothelial cells. Plasmin degrades 
fibrin and fibrinogen into low molecular weight fragments measured clinically as fibrin 
and fibrinogen degradation products (FDP), a process inhibited by PAI-1.  
The basis of the research conducted for my thesis is that the imbalance of the 
coagulation/fibrinolytic pathways caused by Protein C inhibition of the coagulation 
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process and PAI-1 inhibition of fibrinolysis are important factors of the development and 
progression/severity of PGD in lung transplant patients. An irreversible effect caused by 
the coagulation/fibrinolytic imbalance, leads to tissue damage and eventually death, in a 
large number of PGD patients. 
PAI-1 has also been identified as a predictor of death for patients with post trauma 
disseminated intravascular coagulation (DIC), a common predictor of ARDS and death.50  
In other research studies it was concluded that the overall effects of coagulate and fibrin  
formation is yet to be identified and may play an important role in assessing the effects of  
certain therapies for ischemia-reperfusion, a major factor in PGD.51  
Following injury to the endothelial, the coagulation system responds almost 
immediately, forming a clot that is later degraded in the process of fibrinolysis. The entire 
process takes a few minutes. Protein C, an anticoagulant of the coagulation system is low 
in PGD patients, allowing for uncontrolled coagulation coupled with excessive fibrin 
formation due to the increase of PAI-1 ultimately resulting in impaired reduction of fibrin 
clots.   
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Figure 7: Complex Coagulation Cascade 
 
Overall, the effects of DIC, PAI-1 and Protein C levels have clearly been 
associated with ARDS, however this research is yet to be conducted or defined for PGD 
patients. One of the goals of this research was to provide the first evidence that decreased 
levels of Protein-C and increased levels of Plasminogen Activator Inhibitor “PAI-1” in 
circulating plasma contribute to the development of PGD in lung transplant patients. 
2.7. Clinical Factors Impacting PGD Risk and Outcomes 
Following lung transplantation, PGD is the cause of death for a significant 
percentage of transplant recipients.52 Outcomes of PGD are classified as short or long 
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term outcomes. As compared to lung transplant patients without PGD, PGD transplant 
recipients have lower rates of long time survival.6;53-55 Adverse short term outcomes 
include prolonged length of mechanical ventilation, increased ICU length of stay, longer 
hospital stays, as well as increased hospital costs and short-term mortality.9;54;55 
In a cohort study of 252 transplant patients at the University of Pennsylvania, over 
a ten year study, Christie et al identified several clinical risks factors; recipient diagnosis 
of primary pulmonary hypertension (PPH), donor African American race, donor female 
gender, and donor age that significantly associated with the development of PGD in the 
study population.11 In another study conducted over a 12- year period of 259 lung 
transplant patients at two clinical centers in France, discovered a strong correlation of 
donor’s age, degree of gas exchange impairment, graft ischemic time, and severe early 
hemodynamic failure with the development of PGD and mortality, following lung 
transplant.55 Sekline et al also identified for PGD patients, primary risk factors for 30 day 
mortality and longer ICU stays, such as cardiopulmonary bypass, recipients body mass 
index (BMI), as well as use of marginal donors and recipients prior diagnosis of a 
pulmonary hypertensive disorder.56 The research conducted for this thesis takes into 
consideration these risk factors in evaluating the relationship of our biomarkers with PGD 
risk. 
2.8. Donor and Recipient Related Risk Factors and Markers 
Previously, methodological issues significantly hampered early studies of donor 
and recipient related risk factors for PGD.3;13 As a result of inconsistencies in methods 
there has been insufficient evidence to make strong conclusions of association between 
PGD and many potential risk factors, including advanced or young age, race, gender, 
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previous chest surgery, liver dysfunction, renal dysfunction, left heart disease, blood 
transfusion, and single vs. bilateral transplantation, see Table 2:PGD Risk Factors 
Organized by Relationship to Donor or Recipient, Hoffman, Current Opinion in Organ 
Transplantation 2007.  
Strong associations do exist between primary pulmonary hypertension (PPH) and 
development of PGD.13;38;39;48;49;57 In contradistinction, patients with chronic obstructive 
pulmonary disease (COPD) consistently have reduced rates of PGD. Associations with 
secondary pulmonary hypertension are less conclusive. With regard to surgical 
technique-related risk factors, studies adjusting for PPH are suggestive that 
cardiopulmonary bypass is not a risk factor for PGD, and exciting early clinical 
experience is showing that reperfusate modifications are associated with reduced rates of 
PGD.3;13  
Such prior research involved altering the content of the initial reperfusate and 
maintaining a low reperfusion pressure after surgical implantation of 100 (42 single and 
58 double) lung transplant recipients.13;38;39;48;49;57;58 PGD grade was assigned according 
to a modified ISHLT definition; PAO2/inspired oxygen fraction of less than 150 (instead 
of 200) with diffuse infiltrate on the radiograph.58 The modified reperfusion technique 
consisted of a catheter inserted into the main or individual artery with a solution of 
recipient depleted leukocytes; supplemented with nitroglycerin; adjusted for pH and 
calcium level; enriched with aspartate, glutamate, and dextrose; then administered into 
the pulmonary arteries of the newly transplanted lungs(s) for the first 10 minutes of 
reperfusion. However, because of the lack of utilization of standard methodology and 
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distinct grading criteria, this research lacks validity and requires further investigation 
prior to gaining full support of the PGD lung injury research community.  
 
Table 2: PGD Risk Factors Organized by Relationship to the Donor or Recipient 
Timeline Risk factor for PGD Inconsistent 
Donor-related, 
inherent characteristic 
Age < 21 or > 45  
 African-American race * 
 Female gender * 
 Smoker  
Donor-related, 
acquired 
characteristic 
Brain death  
 Trauma  
 Prolonged mechanical ventilation  
 Bronchospasm / Pneumonia  
 Multiple blood transfusions  
 Hemodynamic instability  
Donor-related, 
harvest-related 
Procurement technique  
 Preservation solution and flush technique  
 Storage and transport technique  
 Ischemic time   
Recipient-related, 
inherent characteristic 
Diagnosis of Primary pulmonary 
hypertension 
 
 Secondary pulmonary hypertension * 
 Pro-inflammatory cytokine / chemokine 
imbalance 
 
 Enhanced coagulation / impaired fibrinolysis  
Recipient-related, 
transplantation-
related 
Cardiopulmonary bypass use * 
 Blood product transfusion * 
 Reperfusion technique  
 
 
Other research initiatives provided additional inconsistent evidence because of the 
lack of utilization of standard methods as well as distinct grading criteria for defining 
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PGD. Studies such as the experimentation following transplant of reperfusate, the mean 
Pao2/Fio2 at 6 hours and 48 hours post transplant was 252 ± 123mm Hg and 301 ± 80 
123mm Hg (n=50), respectively. In the research conducted (n=100) patients experienced 
a mean of 2 days on ventilation, four days in ICU and 14 days in the hospital. 2% of 
patients developed sever PGD at 48 hours and the early survival (30 day or in hospital 
mortality) was 97%.58 The group was applauded for their exceptional clinical outcomes, 
no intra-operative deaths among the 100 participants; however, since several factors 
within the reperfusion was changed at once, the authors were unable to decipher which 
component of the modified reperfusion is the active factor responsible for reduction in 
PGD – 48h. In conclusion, Schnickel et al58 provided evidence that modified reperfusion 
in human lung transplantation is associated with a low incidence of severe PGD and 
favorable short term outcomes; however, modifications to the ISHLT grading system and 
other factors may have allowed for potentially favorable study outcomes, such as 
Pao2/Fio2 of less than 150 at 48h in stead of the standard Pao2/Fio2 of less than 200 to 
define severe PGD; the use of potent anti inflammatory drugs, Pao2/Fio2 ratios reported 
were not consistent with previously published research59; and the lack of a control group.  
Experiments to better understand the attenuating effect of mycophenolate mofetil 
(MMF) on inflammatory injury in acute ischemia60 was studied in a Lung ischemia-
reperfusion injury (LIRI) rat model.  The major focus was on transcriptional regulation of 
pro-inflammatory mediators by electrophoretic mobility shift assay (EMSA) for 
transcription factor transactivation and by enzyme-linked immunoassay for BAL 
chemokine protein content. In the rodent LIRI model studied, at 4 hours of reperfusion, 
MMF significantly reduced lung vascular permeability indices (48% reduction), MPO 
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content (48% reduction), and alveolar leukocyte (21% reduction) as well as, reduced 
brochoalveolar lavage monocyte chemoattractant protein 1(MCP-1)(52% reduction) and 
cytokine induced neutrophil chemoattractant (CINC) (37% reduction).60 MMF was found 
to mediate at the transcriptional level via attenuation of early EGR-1 and AP-1 
transactivation to provide protection during lung ischemia-reperfusion induced increases 
in vascular permeability and inflammatory cell sequestration in lung parenchyma and 
alveolar spaces; an activity found to be associated with reduced late MCP-1 and CINC 
protein secretion.60 However application of this research may be limited because it was 
performed in a warm hilar occlusion model of LIRI where as clinical lung transplantation 
is usually performed using cold preservation solutions. 
Recently investigators incorporating ISHLT Working Group definitions into the 
study of recipient related risk factors supported associations between PGD development 
and PPH, and elucidated demographic and transplant-procedure related risk factor 
variables. Research by Whitson, et al studied donor and recipient medical records of 402 
lung transplant patients between 1992 – 2004 utilizing the ISHLT definition to calculate 
the worst PGD grade 48 hours post-operation to identify donor and recipient risk factors. 
Based on the 402 records studied they found that in the first 48 hours post transplant, 
recipient diagnosis was a significant bivariate risk factor; whereas, in the multivariate 
analysis recipient pulmonary artery pressure and transplantation era were associated with 
grade 3 PGD in the first 48 hours postoperatively. In addition, 90 day mortality rate 
associated with the development of ISHLT grade 3 PGF in the first 48 hours 
postoperatively were 17%, versus 9% in the group without grade 3 PGD.61 The research 
conducted by Whitson et al successfully identified lung transplant recipients at high risk 
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for severe PGD based on evaluation of donor and recipient risk factors, as such 
treatments aimed at reducing reperfusion injury might benefit this population of 
transplant patients.61  More research is needed utilizing the standard PGD definitions and 
methodology. 
These variables need to be controlled as potential confounders, taken into 
consideration with biomarker levels and the study outcome, PGD. In addition, in an effort 
to reduce inconsistencies in reporting, this research employed the standard Grade 3 
definition of PGD, as defined by the ISHLT working group. 
2.9. Prior Biomarker Studies in PGD 
Aim 2 of this research will test variables for interaction or as confounding 
variables with the development of PGD. Recent preliminary work suggests that inherent 
donor and recipient characteristics (such as gender, age, and underlying medical 
diagnoses) may play an important role in determining risk of PGD.8 
In one such study, VEGF, which regulates vascular permeability was recently 
determined to be the major mediator of increased vascular permeability induced by 
ischemia reperfusion in an experimental lung injury setting.62 To determine if vascular 
endothelial growth factor (VEGF) could predict PGD in a prospective cohort study of 
150 patients undergoing lung transplantation and 12 healthy volunteers, pre-transplant 
VEGF was measured by Elisa.63 PGD grades 0-3 occurred in 23%, 44%, 21%, and 11% 
of patients, respectively and pre-operative VEGF serum concentrations were significantly 
higher in PGD Grade 3 versus grade(0-2) or the controls63.  PGD grade was determined 
according to the ISHLT guidelines. Based on this research, pre-operative VEGF serum 
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concentrations did identify lung transplant recipients with high PGD risk. VEGF 
screening of future transplant patients could identify those at higher risk for PGD.63 
This previous research of VEGF in the serum of PGD patients shows feasibility of 
biomarker studies, such as the research conducting for this thesis. 
2.10.   Impact of PGD on Outcomes 
In other efforts to identify predictors of PGD, researchers reviewed medical 
records of 402 lung transplant patients to compare the performance criteria employing 
arterial oxygenation to fraction of inspired oxygen (P/F) ratio to an alternative grading 
system employing the oxygenation index (OI)64 from T0 to T48 h post transplantation. 
P/F ratios were measured and grades according to ISHLT guidelines and Oxygenation 
index (OI) was [OI = mean airway pressure/(P/F ration)] was measured. After transplant 
the prevalence of severe PGD (P/F Grade 3) declined from 25% to 15% at T0 to T48, 
respectively; however, the 90 day death rate associated with PGD grade increased with 
Grade, 7% at Grade 1, 12% at Grade 2, and 33% at Grade 3,64 which is consistent with 
previous PGD research.65 Although this research found that grouping patients by P/F 
grade provided the clearest differentiation of 90 –day death rates, T48 OI grade was also 
found to differentiate 90 day death rates.64 In multivariate models, significant risk factors 
for short and long term mortality were P/F grade 3, single lung transplant, use of 
cardiopulmonary bypass and high preoperative mean pulmonary artery pressure. In 
conclusion, this research supported the general consensus that there is an increased risk of 
short and long term mortality and length of hospital stay associated with severe (Grade 3) 
PGD, rapidly identifiable by the ISHLT grading system. However, unlike the research 
conducted for my thesis, this research did not include a 72h time point, did not analyze 
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chest x-rays for the presence or absence of infiltrates, and classified patients with a P/F 
ratio >300 as Grade 1 PGD which is inconsistent with the ISHLT grading system.64 
Beyond the first year following lung transplant, BOS was previously determined 
to be a leading cause of death.66-68 The relationship between PGD survivors and BOS in a 
retrospective cohort study of 334 lung transplant recipients was studied. PGD grade was 
classified according to ISHLT guidelines.  Acute rejection and lymphocytic bronchitis 
were histologically graded by ISHTL criteria, and respiratory specimens were acquired 
for the identification of community acquired respiratory viral infections including 
brochoalveolar lavage, brochial washings and nasopharnygeal swabs with virus specific 
immunofluorescent labeling of cytocentrifugation preparations. This research provided 
evidence of an association of PGD with an increased risk of BOS directly related to the 
severity of PGD, independent of acute rejection, lymphocytic bronchitis, and community 
–acquired respiratory viral infections.69 Although, single lung transplantation, 
cardiopulmonary bypass, and preoperative diagnosis were associated with BOS, they 
were not determined to be significant associations. 
Prior PGD research regarding outcomes focused on the clinical and histological 
sequence of PGD following lung transplant.  In one such study,  180 single lung 
transplants histological specimens were obtained by protocol flexible bronchoscopy 
surveillance with routine TBB and BAL at 2, 4, 6, 12, 26, 52, 78 and 104 weeks. 63% 
PGD cases, as defined by the presence of diffuse radiological infiltrate, as well as a worse 
90 day postoperative mortality rate and 3 year survival was reported for patients that 
developed PGD following lung transplant.70 In addition, patients without PGD had a 
significantly higher FEV (median 59%) than patients with PGD (median 54%), required 
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< 48 h ventilation and tracheostomy and less time in ICU; however the total hospital stay 
was not significantly different in Non-PGD versus PGD patients.70 There was no 
significant correlation between severity of infiltrate or PaO2:FiO2 ratio and progression to 
BOS grades 03-3; however, there was a strong correlation between the increasing severity 
of radiological infiltration and the histological findings of organizing pneumonia (p = 
0.0003), comprising DAD (p < 0.0001) and/or BOOP (p= 0.03). In conclusion, Burton et 
al provided evidence that PGD appearance and severity are closely correlated with 
histological findings of diffuse alveolar damage, lung function and overall recipient 
survival.70  See Table 3:Interventions to Reduce Risk of PGD or Treatment, Hoffman 
2007, for a summary of previous research supporting various interventions aimed to 
reduce risk or to treat PGD. 
  
27
Table 3: Interventions to Reduce Risk of PGD Development or Treat PGD*  
Intervention 
class 
Target risk factor Intervention (a experimental, clinical) 
(b experimental, laboratory) 
Donor-related Brain death / neurogenic 
pulmonary edema 
Steroids 
(Harvest) Hypotension Vasopressors 
 Lung infection Antibiotics / BAL for Culture 
 Hypertension Antihypertensives b 
 Lung Inflammation Mycophenolate mofetil (MMF) IV b 
 Lung inflammation / coagulation Carbon monoxide inhalation b 
 Lung function B2-adrenoreceptor agonist inhalation 
b 
 Atelectotrauma, membrane 
damage 
Ventilation during lung procurement 
 Free radical and T-cell mediated 
damage 
Indoleamine 2,3-dioxygenase (IDO) 
 Poor distribution of preservation 
solution 
Prostacyclin infusion 
 Membrane damage Extracellular-type preservation 
solution a 
 Lung inflammation Aprotinin containing preservation 
solution 
 Membrane damage, lung 
inflammation 
Hypothermic preservation solution 
(4°C) 
 Membrane damage, lung 
inflammation 
Retrograde flush of solution 
 Hyperoxic damage Storage inflation gas FiO2 0.30 to 0.50 
 Barotrauma, membrane damage Measured lung inflation for storage 
 Membrane damage, lung 
inflammation 
Hypothermic storage (4°C) 
Recipient-
related 
Pro-inflammatory state Avoidance of cardiopulmonary 
bypass a 
(Transplantation) Hypoperfusion Use of cardiopulmonary bypass a 
 Lung inflammation / coagulation Carbon Monoxide inhalation b 
 Membrane damage / lung 
inflammation 
Modified (leukocyte-depleted) 
reperfusate a 
 Membrane damage / lung 
inflammation 
Reperfusate protocol duration and 
pressure  
*Assuming otherwise acceptable recipient and donor candidates 
Although some of the previous studies utilized a slightly modified ISHLT grading 
system, excluding the T72 time point, they all provided a general consensus in favor of 
the PGD definition and grading guidelines of the ISHLT and suggest that additional 
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categorization coupled with pre-transplant therapies might help to improve patient 
outcomes following lung transplant.  The previous research provides evidence for this 
thesis, that PGD is really important in general, so preventing it would be good and 
improve outcomes. To assess predictors and outcomes of PGD, ISHLT PGD Grade 3 
definition was employed for the research conducted and clinical variables were assess 
regardless of their significance to biomarker levels. 
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3. METHODS 
3.1. Overview of Design 
This research tests the hypothesis that increased levels of PAI-1 and decreased 
levels of Protein C play an important role in PGD by measuring PAI-1 and Protein C 
levels in lung transplant patients, pre, immediate post-op, 24, 48 and 72 hours post 
transplant and correlating the Protein C and/or PAI-1 levels with the stage of PGD (as 
described in the Outcome Definition). In addition, clinical risk variables were assessed to 
determine the potential confounding effects, if any, of each factor on biomarker levels 
and PGD outcome. PAI-1 and Protein C plasma levels were measured at pretransplant, 6, 
24, 48, and 72 hours post transplant in the study population. The primary outcome is 
Grade 3 PGD at 72 hours post transplantation.2;11 
3.2. Study Population and Biomarker Samples  
The samples for this research were obtained from participants in the Lung 
Transplant Outcomes Group “LTOG” a multicenter study of PGD conducted at seven 
centers (University of Pennsylvania, Columbia, UAB, Vanderbilt, Stanford, Johns 
Hopkins and Michigan). With the participant’s consent, to investigate biological markers 
of PGD plasma samples utilized for this research were obtained pre and post lung 
transplant from 131 sequential lung transplant subjects at the seven centers listed above. 
Samples from all seven clinical centers are obtained according to protocol and shipped to 
the central facility at the University of Pennsylvania where this research is being 
conducted. In addition to plasma samples collected pre and post transplant for analysis, 
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extensive clinical variables were also obtained. The clinical data obtained was utilized in 
association with the biomarker analysis in models to predict PGD outcomes.  
The study design was a prospective cohort study. The majority of the data 
collected for the biomarker analysis was collected and analyzed post transplant as the 
participant was observed in the immediate days following lung transplant. Since the 
participants remain in the hospital for at least the three-day post transplant phase, there 
was very little to no loss to follow-up. In addition, the cohort study poses no selection 
bias because there is no randomization schema; all lung transplant participants at the 
participating clinical centers were approached with study participation. The study 
consisted of three populations: lung transplant recipients that develop PGD, lung 
transplant recipients that do not develop PGD following transplant and a group of non-
lung transplant controls.  
The inclusion criteria for the cohort study were patients undergoing lung 
transplant at the participating clinical centers and at least 13 years of age. Exclusion 
criteria were: patients, undergoing combined organ transplant, other than heart-lung 
combined transplantation. Children, 13 years and younger were excluded from 
participation because the risk of PGD and patterns of disease are different in this age 
group than the adult population.  
3.3. Definition of the Primary Outcome: PGD 
The primary outcome for this research is the risk of development of PGD 
(primary graft dysfunction) following lung transplant. The definition of PGD applied to 
the proposed research is the International Society of Heart and Lung Transplantation 
(ISHLT) Grade 3 PGD (PaO2/FiO2<200 with radiographic infiltrates) at 72 hours, 
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excluding secondary cause of graft dysfunction.1-3 In the proposed research, a confirmed 
outcome will specifically be defined as: (1)in the transplanted lung/s, 72 hour post 
transplantation presence of alveolar infiltrates, sparing the non-allograft lung; (2) at 72 
hours a less than 200 ratio of arterial partial pressure of oxygen (PaO2) to fraction of 
inspired oxygen (FiO2); (3) elimination of possible secondary cause of graft dysfunction, 
including: including a) cardiogenic pulmonary edema defined as a pulmonary artery 
occlusion pressure of greater than 18 cm or resolution of infiltrates with effective 
diuresis, b) pathologic evidence of rejection, c) pneumonia as evidenced by the presence 
of fever, leukocytosis, and purulent secretions with positive cultures on bronchoscopy 
during the first three postoperative days, and d) pulmonary venous outflow obstruction by 
clot or kinking as demonstrated by transesophageal echocardiogram or direct inspection 
on surgical re-exploration or postmortem examination; (4) in scenario of transplant 
recipients’ death prior to 72 hours post-transplant, to be classified as PGD outcome the 
subject must have met all of the above outcome criteria and as the predominant process 
upon histological examination of the allograft lung must evident of diffuse alveolar 
damage.1;2;3;57 
The above categories of PGD take into account the major entities of the outcome 
definition, oxygen exchange and the presence or absence of diffuse infiltrates in the 
allograft, sparing the native lung, to determine the grade.  
This research looked at the outcome of PGD at 72 hours as well as the grade of 
PGD at various time points post transplant; however, for the purposes of this research the 
primary outcome, PGD, will be defined as PGD Grade 3 at 72 hours post allograft. 2;3 
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PGD at 72 hours post allograft has been adopted as the standard definition of 
PGD because it excludes secondary causes of graft dysfunction commonly seen in earlier 
stages/hours post transplant prior to 72 hours.1-3 In previous studies of PGD, other forms 
of acute lung injury which were incorrectly diagnosed as PGD because there systems 
tend to favor early onset of PGD. The primary outcome of this proposed research, Grade 
3 PGD as defined at 72 hours post allograft, is associated with the worst clinical 
outcomes, pathological evidence of acute lung injury, and clear differences in Biomarkers 
of lung injury. As such, this research is one of the first to utilize the distinct standardized 
Grade 3 criteria for defining the outcome, PGD in lung transplant recipients. 
3.4. Protein C Biochemical Analysis 
Protein C is a serine protease that circulates in the blood as an inactive zymogen 
precursor. It binds to the thrombin/thrombomodulin receptor and inhibits thrombosis and 
enhances the fibrinolytic system to eliminate blood clots.  
When activated, Protein C, a vitamin K dependent protein, can inhibit coagulation 
and stimulate fibrinolysis. Due to the presence of a specific Protein C inhibitor, current 
amidolytic Protein C assays have reduced ability to directly assay for Protein C utilizing 
whole blood. For this research a functional chromogenic assay, which utilizes a rapid 
Protein C activator derived from snake venom of the copperhead snake Agkistrodon 
contortix was employed. The quantitative measurements of Protein C levels were 
measured. One research question for this thesis is whether or not the research subjects are 
losing Protein C, the inactive zymogen, not the thrombomodulin receptor; which is why 
we are using a chromogenic assay to quantitatively measure the Protein C zymogen. In 
the proposed research we are measuring the amount of pro-protein C that is left in the 
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blood utilizing the ACTICHROME® Protein C assay. The Protein C assay is produced 
by American Diagnostica.  
In this chromogenic assay, Protein C in the patient’s plasma sample is activated 
by specific snake venom. The activated protein C cleaves a synthetic substrate that 
resembles the natural substrate of protein C, liberating a chromogenic substance that can 
be measured spectrophotometrically.71 The peptide has a C terminal paranitrite; 
absorbance is greatly enhanced when the peptide is free of the paranitrite. We are 
utilizing the BIOTEC Spectrometer – Power Wave XS for this research. 
The Protein C assays were performed in 96 well microtest with control plasma of 
known Protein C levels. The control plasma, for this assay consisted of pooled normal 
human plasma, with previously determined Protein C concentration. The control plasma 
was diluted to 125%, 100%, 75%, 50%, 25%, and 0% Protein C and utilized as standards 
for the assay. Two assays, an assay with activator, as well as an assay without activator 
(saline assay), was run for each sample. To ensure data quality, duplicate assays (2 saline 
assays and 2 activator assays) were performed for every sample, including the Protein C 
standards. 
The Delta absorbance for this assay was then calculated by subtracting the 
absorbance obtained for the sample in the presence of saline from the absorbance 
obtained for the sample assayed in the presence of activator. 
Δ A405 = A405 (sample with Activator) - A405 (sample with saline) 
The Delta Absorbance obtained at 405 nm for each Protein C standard was then 
plotted against its corresponding percentage. The Protein C level in the plasma specimen 
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was determined by interpolation from the calibration curve. A standard curve was 
generated each time the assay was performed.  
Protein C analysis for this research was conducted on multiple samples over 
several days on each study participant. Protein C concentration was measured at various 
time points pre and post transplant to determine the average Protein C concentration, over 
time. 
Protein C inhibition is a relatively slow reaction, which allows for some activity 
prior to complete inhibition. The rate of inhibition can vary depending on the amount of 
substrate that is activated. This assay is curved and non-linear because it is a complex 
assay with rapid activation prior to complete inhibition.  
This assay was utilized because it was highly reproducible and it has been 
previously utilized in published research of Protein C. This chromogenic assay allows us 
to measure how much potentially active Protein C is present in each sample; where as, 
utilization of an ELISA (Enzyme Linked Immunosorbent Assay) would provide us with 
the activated, as well as inhibited, Protein C. 71 This assay is a very complex assay with 
rapid activation prior to complete inhibition.  
Plasma samples were obtained for each participant and run in duplicate against a 
Protein C standard of known concentration. Samples were assayed using a chromogenic 
assay, which utilizes a rapid Protein C activator derived from snake venom to measure 
the quantitative Protein C levels. See Figures 8-12 below. 
3.5. PAI-1 Biochemical Analysis  
Plasminogen Activator Inhibitor 1 (PAI-1), is found in various tissues and cell 
types including adipose tissues of the heart and lungs, as well as in platlets.72;73 For this 
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research, human Plasminogen Activator Inhibitor Type-1(PAI-1) antigen in plasma was 
being measured utilizing the IMUBIND® Plasma PAI-1 Elisa, an enzyme linked 
immunosorbent assay. Levels of PAI-1, a serine protease inhibitor, have been associated 
with various thrombotic and fibrinolytic complications. Unlike Protein C, PAI-1 
inhibition of TPA is a very rapid reaction. 
This assay utilizes microwells coated with a mouse monoclonal antibody directed 
against human PAI-1. PAI-1 standards and plasma samples are added to the wells and the 
antibody captures the PAI-1 antigen present during an incubation period. A peroxidase 
conjugated goat polyclonal antibody against human PAI-1 is added to the well and this 
conjugate binds to the captured PAI-1 molecules. All unbound material is washed away 
and a peroxidase reactive enzyme substrate, orthophenylenediamine (OPD) is added to 
the wells. The subsequent peroxidase/substrate reaction yields a yellow colored solution. 
Addition of sulfuric acid stops the reaction and turns the solution color orange. The 
absorbance of the solution was measured at 490 nm. The absorbance is directly 
proportional to the amount of PAI-1 present in the sample. 
For this analysis unclotted citrated blood was utilized. In preliminary analysis 
most of the samples for this research contained over 50ng/ml of PAI-1, so each sample 
was diluted 1:3 in a PAI-1/TPA depleted plasma standard; the dilution factor was taken 
into consideration when determining the final PAI-TPA activity during the analysis 
phase. For PAI-1 analysis , 20ul of each patient’s plasma sample was diluted in 40ul of 
PAI-1/TPA depleted plasma; 20ul of each diluted sample was then utilized for the Elisa 
assay. In addition, each assay consisted of plasma standards and a QA sample. All of the 
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samples analyzed, including the PAI-1 Standards, were assayed in duplicate. The PAI-1 
standard was assayed at 0, 12.5ng/ml, 25ng/ml, and 50ng/ml.  
After completion of the assay and the absorbencies are known, a standard curve 
was then constructed by plotting the mean absorbance value measured for each PAI-1 
standard versus its corresponding PAI-1 concentration. A standard curve was constructed 
each time the assay was performed. The PAI-1 concentration of the sample was then 
interpolated directly from the standard curve.  
A Quality Assurance, fibrinolysis reference plasma of know PAI-1 activity, was 
utilized with each assay. We utilized this specific PAI-1 assay because it was previously 
utilized in published PAI-1 studies and because it’s was a stable, as well as, reproducible 
assay. After completion of the assay and the absorbencies were known, a standard curve 
was then constructed by plotting the mean absorbance value measured for each PAI-1 
standard versus its corresponding PAI-1 concentration. A standard curve was constructed 
each time the assay was performed. The PAI-1 concentration of the sample is then 
interpolated directly from the standard curve. 
Prior to proceeding with complete biomarker analysis, premilinary studies were 
conducted to determine the following criteria (See Figures 13-16 below): 
• If the measurement of PAI-1 association in Standard and QA samples 
yielded reproducible results 
• If the standard curve used to derive PAI-1 concentration in the samples, as 
seen in the standard curve for the PAI-1 assay was linear. 
• If there was measurable variability between subjects and PAI-1 levels 
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• If there was sufficient variability in PAI-1 level between subjects to test 
hypotheses of Aim 2 (Association of PAI-1 with PGD) 
3.6. Statistical Analysis Plan   
Longitudinal trends were graphed using excel. A student t-test was employed to 
compare Grade 3 PGD at 72 hours to cases without PGD at 72 hours based on PAI-1 and 
Protein C levels 24 hours post transplant. T-test (continuous) and chi-square (categorical) 
were employed to identify potential donor and recipient risk factors.  In cases with PGD, 
to further assess the effects of confounding variables on the 24 hour biomarker levels we 
conducted multivariate logistic regression models. Only one variable was assessed at a 
time in an effort to not over-fit the model. Variables included in the model were not 
based on statistical significance in the univariate analysis but were chosen based on prior 
knowledge and previous research.  Statistical comparisons were performed using Excel 
and SAS (SAS Institute, Cary, NC).74  
Within the scope of the primary aims we will evaluate the association of the 
change over time of the biomarkers as defined at different time intervals prior to 
transplant as well as immediate, 24, 48 and 72 post transplant: 
Prior = if hours ≤ 0 then time="Pre-Transplant; 
Study Day “IPT” = if hours ≥ 0 hours and hours ≤ 12 then time="Immediate Post" 
Transplant; 
Study Day “1” = if hours ≥ 12 and hours ≤ 36 then time= “Day 1” Post Transplant; 
Study Day “2” = if hours ≥ 37 and hours ≤ 60 then time="Day 2" Post Transplant; 
Study Day “3” = if hours ≥ 61 and hours ≤ 84 then time="Day 3" Post Transplant. 
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In addition, based on the levels of each biomarker at the various study time 
intervals outlined above, we hope to further test the assocaiton with the outcome 
definition, when adjusting for confoudning. To further assess how changes in Protein C 
or PAI -1 levels effect the study outcome (PGD), a logistic regression model was 
developed. The model assessed the variability in PGD as explained by the variability in 
Biomarker concentration accounting for “x”: 
   PGD=β1Biomarker + β2X 
For the model developed, the outcome “PGD” was the dependent variable with 
the biomarkers and/or confounder variable as the “independent” variables. In an effort to 
not over-fit the model, only one variable was assessed at a time.75-78 
 
3.7. Sample Size and Power  
For this research power estimates and sample size were estimated based on 
previous research in the PGD field.  This study was powered to detect a difference of 
PAI-1 levels between the PGD and Non-PGD groups.. Researchers were able to detect a 
statistically significant difference in PAI-1 levels between of about 129 ng/ml.   Power 
for this research was based on an alpha of 0.05 at 95% CI and a mean difference between 
the two groups of 129 ng/ml with a sample size of 132 subjects, this research was 
powered at a 99.5% level to detect a difference in the PAI-1 levels between the PGD and 
Non-PGD groups. 
 
 
 
  
39
4. RESULTS  
4.1. Identification of Outcome Cases 
For this research, upon review of each participant’s post transplant data, 15 % (19 
of 131) met the outcome definition and as thus were considered the PGD cases, all others 
were considered Non-PGD. Identification of 15% outcome cases within the sample 
population is consistent with previous PGD research that reported on average, 10-25% 
PGD cases.1;2;9  
The research subjects had varying grades of PGD.  The outcome definition is 
designed based on guidelines consistent with ARDS, an established syndrome.  For this 
research, the most extreme definition of PGD (Grade 3) was utilized to identify outcome 
cases as to not confuse other causes of graft failure or rejection with the actual PGD 
outcome. 
4.2. Distribution of Clinical Variables in PGD and Non-PGD 
To take into account clinical risk factors, as well as to provide additional evidence 
of donor and recipient clinical risk factors associated with the development of PGD, the 
relationship of clinical factors and PGD was evaluated.   
There were no significant differences between the PGD and Non-PGD groups in 
regards to the donor variables assessed, which included donor’s age, gender, race, history 
of smoking and donor’s oxygen level (see Table 4). 
 
 
 
 
  
40
 
Table 4:  Donor Clinical Risk Characteristics: Non-PGD vs. PGD 
Variable Non-PGD (n=113) 
PGD 
(n=19) p Value 
Age, yr: mean (95% Cl) 30 (28, 32) 33 (26, 40) 0.37 
Donor Female sex, % 35 47 
Donor Male sex, % 65 53 
0.32 
Donor race, % 
Asian 2 0 
Black 16 5 
Caucasian 70 74 
Hispanic 10 21 
Other  2 0 
0.44 
Donor History of Smoking, %  
Yes 41 53 0.58 
Donor Oxygen – Low, 
mean (95% Cl) 320 (285,354) 315 (203, 427) 0.92 
Donor Oxygen – High, 
mean (95% Cl)  506 (482, 531) 500 (423, 574) 0.83 
 
 
While there was no statistical significant difference between the PGD and Non-
PGD groups in regards to donor’s  age, gender, race, history of smoking and donor’s 
oxygen level; in regards to recipient variable; recipients diagnosis and  procedure type as 
well as the administration of packed red blood cells (PRBC), platelets, pulmonary arterial 
systolic pressure (PASP), and pulmonary arterial diastolic pressure (PADP) within the 
first 24 hours post transplant were all determined to be statistically different between the 
two groups, PGD and Non-PGD.  
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Table 5: Recipient Clinical Risk Characteristics: Non-PGD vs. PGD 
Variable Non-PGD (n=107*) 
PGD 
(n=17*) p Value 
Age, yr: mean (95% Cl) 53 (50, 55) 45(35, 55) 0.05 
Female sex, % 44 42 0.83 
Recipient Race, % 
Asian 0 6 
Black 7 12 
Caucasian 91 76 
Hispanic 2 0 
Other 1 6 
0.05 
Recipient Race, % 
Caucasian 91 76 
Non-Caucasian 9 24 
0.09 
Procedure Type, % 
BL 45 76 
HL 2 6 
LL 29 18 
RL 24 0 
0.03 
Procedure Type, %    
SL 54 19 
BL 46 81 
0.08 
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Table 6: Additional Recipient Clinical Risk Characteristics: Non-PGD vs. PGD 
Variable Non-PGD (n=107) 
PGD 
(n=17) pValue 
 
Recipient Diagnosis, % 
CF* 10 12 
COPD** 58 18 
IPF*** 26 53 
PPH**** 2 18 
Other 4 0 
    
0.001 
Pre-oxygen (yes), % 79 89 0.520 
Use of cardiopulmonary 
bypass, (%) 24 76 <0.001 
Packed red blood cells 
:mean (95%, Cl)* 393 (213, 574)
1205 
(658,1753) 0.002 
Platelets :mean (95%, Cl)* 76 (33, 119) 287 (5.9, 568) 0.006 
Fresh frozen plasma :mean 
(95%, Cl)* 227 (129, 326) 397 (104, 691) 0.210 
Pulmonary artery systolic 
pressure (at induction): 
mean (95%, Cl) 
40 (37, 43) 69 (50, 89) <0.001 
Pulmonary artery diastolic 
pressure (at induction): 
mean (95%, Cl) 
21 (19, 23) 35 (24, 47) <0.001 
Ischemic Time 1 (first lung, 
minutes): mean (95%,Cl) 214 (108, 225) 230 (206, 255) 0.75 
Ischemic Time 2 (second 
lung, minutes): mean 
(95%,Cl) 
344 (318, 370) 311 (247, 375) 0.25 
* CF=Cystic Fibrosis; COPD = Chronic Obstructive Pulmonary Disease;  
IPF= Idiopathic Pulmonary Fibrosis; PPH=Primary Pulmonary Hypertension;  
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4.3. Standardization and QA of Biomarker Measurement Assays 
4.3.1. Measurement of Protein C 
Plasma samples were obtained for each participant and run in duplicate against a 
Protein C standard of known concentration. Samples were assayed using a chromogenic 
assay, which utilizes a rapid Protein C activator derived from snake venom to measure 
the quantitative Protein C levels. All samples, including controls and QA samples were 
run in duplicated. 
Preliminary analysis indicated that the Measurement of Protein C in standard 
samples yielded reproducible results and illustrated that the activator for the assay is 
reproducible and reaches the expected absorbance at 405nm, as compared to the control, 
which was the standard curve used to derive Protein C concentration in the samples, see 
Figure 8.  
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Figure 8: Stability of Protein C Standards 
 
 
Initial test indicated that the test mechanism was comparable to the sample type 
and that the test Protein C standards performed with in the expected range as specified for 
QA measures, see Figures 9-10. 
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Figure 9: Protein C Activator vs Saline 
 
 
 
The Delta Absorbance obtained at 405 nm for each Protein C standard was then 
plotted against its corresponding percentage. The Protein C level in the plasma specimen 
was determined by interpolation from the calibration curve. See Figure 10. 
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Figure 10: Protein C Standard Curve 
 
 
 
All samples were run in duplicate. Duplicate assays performed on the same 
samples indicate that Protein C measurement was reproducible in the samples utilized for 
this research, as illustrated below in Figure 11. 
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Figure 11: Reproducibility of Protein C Measurement in LTOG Samples  
 
Of note, subject 1032 had no evidence of PGD and has high Protein C levels, 
whereas subject 1340 had evidence of PGD and lower levels or Protein C. 
 
Preliminary analysis with several participant samples, collected overtime pre and 
post lung transplant provided evidence there was sufficient variability in Protein C level 
between subjects selected randomly from the cohort to test the hypotheses of Aim 1 
(Association of Protein C with PGD), see Figures 11 and 12. 
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Figure 12: Variability in Protein C Level of Subjects at different time points 
 
 
There was sufficient variability in Protein C levels between subjects to test 
hypotheses of Aim 1 (Association of Protein C with PGD). Samples were measured at 
study time 0, 24, 48, and 72 hours post transplant. The standard curve described above 
was utilized to derive Protein C concentration of the patient samples, at  405 nm 
absorbance. As illustrated in Figure 12 above, there was good variability between 
subjects in Protein C level.  
 
4.3.2. Measurement of PAI-1 
For this research, human Plasminogen Activator Inhibitor Type-1(PAI-1) antigen 
in plasma is being measured utilizing the IMUBIND® Plasma PAI-1 Elisa, an enzyme 
linked immunosorbent assay. For PAI-1 analysis purposes, 20ul of each patient’s plasma 
sample was diluted in 40ul of PAI-1/TPA depleted plasma; 20ul of each diluted sample 
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sample. All standards and samples were run in duplicate. All of the samples analyzed, 
including the PAI-1 Standards, were assayed in duplicate.  
The PAI-1 standard was assayed at 0, 12.5ng/ml, 25ng/ml, and 50ng/ml. 
Duplicate PAI-1 assays performed on consecutive days on the same standards yielded 
reproducible results, as illustrated in Figure 13. 
 
 
Figure 13: Standardization of PAI-1 Assay 
 
 
 
 
The standard curve used to derive the PAI-1 concentration in the samples, as seen 
below in Figure 13, is linear. The equation of the standard curve was then utilized to 
interpolate the PAI-1 plasma levels in the test samples, see Figure 14. 
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Figure 14: PAI-1 Standard Curve   
 
After completion of the assay and the absorbencies are known, a standard curve 
was then constructed by plotting the mean absorbance value measured for each PAI-1 
standard versus its corresponding PAI-1 concentration. A standard curve was constructed 
each time the assay is performed. The PAI-1 concentration of the sample was then 
interpolated directly from the standard curve.  
PAI-1 results in five patients’ samples selected randomly from the LTOG as 
illustration from the entire cohort. Samples were measured at study time 0, 24, 48, and 72 
hours post transplant. The standard curve, described above, was then  
used to derive PAI-1 concentrations at 490 nm absorbance. PAI-1 measurements were 
reproducible and there was good variability between subjects’ PAI-1 levels, Figure 15. 
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Figure 15: Reproducibility of PAI-1 Measurement 
 
 
Also, as illustrated in Figure 16 below, there was sufficient variability in PAI-1 
levels over the 72 hour post transplant study period in subjects PAI-1 levels to test the 
association of PAI-1 with PGD. 
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Figure 16: Variability in Plasma PAI-1 Levels 
 
 
Based on these biomarker assay results, we concluded: 1) there was sufficient volume of 
samples available to conduct the proposed research; 2) measurement of Protein C was 
reproducible with a good standard curve; 3) Protein C levels in the LTOG samples 
showed adequate variability to test hypotheses; 4) measurement of PAI-1 was 
reproducible with a good standard curve; 5) PAI-1 levels in LTOG samples showed 
adequate variability to test the hypothesis. 
4.4.  Analysis of Association of Protein C and PAI-1 with PGD Risk 
Quantitative Protein C levels were obtained with the utilization of a functional 
chromogenic highly-reproducible assay, utilized in prior research. PAI-1 levels were 
obtained by an ELISA with a mouse monoclonal antibody directed against human PAI-1, 
as detailed above. Participants’ samples were collected prior to transplant as well as 
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immediately (within 6 hrs), 24, 48, and 72 hours post transplant and analyzed for both 
Protein C and PAI-1 biomarker levels. Samples were also obtained pre transplant for 
participants. Duplicate measures were averaged to obtain one biomarker concentration 
for each study day.  
 
Table 7: Biomarker Concentration by Participant Identification (PID) Overtime 
Biomarker  Time  N Mean Std. Dev p 
PAI-1 Initial 122 198 116 
PAI-1 Final 113 92 83 
<0.01 
Protein C Initial  112 83 33 
Protein C Final 117 102 37 <0.01 
      
 
 
 
 
PAI -1 and Protein C measurements overall presented a significant level of 
variation in the sample concentrations. Overall, there was a statistically significant 
difference (P=<.001) in the means of both the initial and final PAI-1 as well as the initial 
and final Protein C biomarker levels. This provides additional evidence to the proposed 
hypothesis that changes in these biomarker levels post transplant play an important role 
in the development of PGD.  
Based on analysis of the two groups, PGD and Non-PGD,  there is no statistically 
significant difference (P = 0.067) in the measurement techniques for each group across 
time points of collection. Therefore, variation in PGD vs Non-PGD biomarker levels was 
not due to differences in measurement collection over time as shown in Table 8. 
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Table 8: PGD vs. Non-PGD: Sampling Time 
  
N Mean (Hours) Std Dev p 
PGD 17 24 5.6 
Non-PGD 107 25 6.2 
0.46 
 
4.5. Summary of Longitudinal Biomarker Analysis: PGD vs. Non-PGD  
PAI-1 levels in PGD patients were consistently higher than Non-PGD patients 
over the 72 hour study period, as illustrated below in Figure 17.   
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Figure 17: PAI-1 Biomarker Levels Over Time: PGD vs. Non-PGD 
 
 
Protein C levels in PGD patients were consistently lower than the Non-PGD 
group over the 72 hour post transplant study period, see Figure 18. 
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Figure 18: Protein C Biomarker Levels Over Time: PGD vs. Non-PGD 
 
 
 
4.5.1. Pre-Transplant Operative Levels and Risk of PGD 
Pre transplant biomarker levels were assessed between the two groups, PGD vs Non-
PGD and there was a statistically significant difference in both PAI-1 levels as well as 
Protein C levels prior to transplant; however the pre transplant time interval was not a 
standardized data collection point for this research and consisted of various time intervals 
pre transplant ranging from several months to one day prior to transplant as well as 
multiple collection points for some participants.  
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Table 9:Comparison of Pre-Operative Biomarker Levels  
(N≤0hrs) 
 
Biomarker  PID N Mean Std. Dev p 
PAI-1 
(ng/ml) 
PGD 37 168 127 
PAI-1 
(ng/ml) 
Non-PGD 89 115 108 
0.02 
Protein C 
(% control) 
PGD 27 82 44 
Protein C 
(% control) 
Non-PGD 79 117 43 
<0.01 
 
 
 
 
4.5.2. Immediate Post Operative Levels and Risk of PGD 
The association of immediate post operative levels of Protein C and PAI-1 were 
tested with PGD defined as a categorical outcome on Day 3. 
 
 
Table 10:Comparison of Immediate Post-Operative Biomarker Levels  
(0-11hrs) 
 
Biomarker  PID N Mean Std. Dev p 
PAI-1 
(ng/ml) 
PGD 12 271 139 
PAI-1 
(ng/ml) 
Non-PGD 100 191 109 
0.020 
Protein C 
(% control) 
PGD 12 74 25 
Protein C 
(% control) 
Non-PGD 97 94 33 
0.008 
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Immediate Post transplant there was a statistically significant difference in both the PAI-1 
and Protein C levels, p=0.02 and <0.008, respectively, between the PGD and Non-PGD 
group.  The PGD group had significantly higher PAI-1 levels and lower Protein C levels 
than the Non- PGD group. 
 
 
4.5.3. Post Operative Levels on Day 1 and Risk of PGD 
The association of levels of Protein C and PAI-1 with PGD were also assessed at 
Day 1 Post transplant defined as a categorical outcome on Day 3. 
 
 
Table 11:Comparison of Biomarker Levels Post Op Day 1  (12-36hrs)  
Biomarker  PID N Mean Std. Dev p 
PAI-1 
(ng/ml) 
PGD 19 235 119 
PAI-1 
(ng/ml) 
Non-PGD 112 106 81 
<0.01 
Protein C (% 
control) 
PGD 18 74 62 
Protein C 
(% control) 
Non-PGD 109 90 34 
 0.13 
 
 
 
At Day 1 post transplant (12-36 hours) there continued to be a statistically 
significant difference (p=<0.01) in the PAI-1 levels between the PGD and Non-PGD  
groups. The PAI-1 levels in the PGD group continued to be significantly higher than the 
PAI-1 levels in the Non-PGD group.  Although the PGD group, at Day 1 continued to 
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have a lower Protein C level than the Non-PGD group, it was not a statistically 
significant difference in the mean Protein C levels of the two groups, p=0.13. 
 
4.5.4. Post Operative Levels on Day 2 and Risk of PGD 
This research tested the association of the pre operative levels of Protein C and 
PAI-1 at Day 2 Post Transplant with PGD defined as a categorical outcome on Day 3.  
 
 
Table 12: Comparison of Biomarker Levels Post Op Day 2  (37-60hrs) 
 
Biomarker  PID N Mean Std. Dev p 
PAI-1 (ng/ml) PGD 15 118 104 
PAI-1 
(ng/ml) 
Non-PGD 91 76 72 
0.056 
Protein C (% 
control) 
PGD 15 74 26 
Protein C (% 
control) 
Non-PGD 89 97 29 
0.005 
 
 
 
 
At Day 2 post transplant (37-60 hours) the PGD group continued to have 
significantly higher PAI-1 levels as compared to the Non-PGD group, p=0.056. In 
addition, unlike Day 1, at Day 2 there was a statistically significant  difference in the 
mean Protein C levels between the PGD and Non-PGD group, p=0.005. The PGD group 
had a significantly lower mean Protein C level than the Non–PGD group, 74 vs 97% 
control, respectively.   
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4.5.5. Post Operative Levels on Day 3 and Risk of PGD 
This research also tested the association of the post operative levels of Protein C 
and PAI-1 at Day 3 Post Transplant with PGD defined as a categorical outcome on Day 
3.  
 
Table 13:Comparison of Biomarker Levels Post Op Day 3  
(61 - 84hrs) 
 
Biomarker  PID N Mean Std. Dev p 
PAI-1 (ng/ml) PGD 13 110 112 
PAI-1 
(ng/ml) 
Non-PGD 93 80 73 
0.19 
Protein C (% 
control) 
PGD 13 87 33 
Protein C (% 
control) 
Non-PGD 91 110 31 
0.02 
 
 
 
At study Day 3 Post Transplant, although the mean PAI-1 levels in the PGD 
group continued to be higher than the Non-PGD group (110, 80ng/ml, respectively). At 
Day 3 post transplant the difference in the PAI-1 levels between the PGD and Non-PGD 
group, was no longer statistically significantly different, p=0.19.  Differences in Protein C 
levels between the PGD and Non-PGD group at Day 3 continued to be statistically 
significant, p=0.02. At Day 3 the PGD grouped had significantly lower mean Protein C 
levels than the Non-PGD group, 87 vs 110% control, respectively. 
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4.6. Analysis of Potential Confounder Variables: PGD Logistical 
Regression Model   
Variables for the logistic regression model were selected based on previous research.  
The model assessed the variability in PGD as explained by the variability in Biomarker 
concentration accounting for “x”: 
 
   Logit P(PGD)=β1Biomarker + β2X 
 
The increase in risk (odds ratio) for PGD associated with each 44% decrease in 
protein C level at Day 1 post transplant was 0.215 (95% CI: 0.077, 0.594; p=0.003).  The 
increased risk for PGD associated with each 88 ng/ml increase in PAI-1 levels at Day 1 
post transplant was 2.209 (95% CI: 1.460, 3.344; p=<0.001). The association of both 
Protein C and PAI-1 with PGD were independent of all potential confounders, see Table 
14. 
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Table 14:Logistical Regression Model:Biomarker Levels and Potential Confounders 
T=Study Day 1(12-36hrs Post Transplant) 
Variable Protein C 
Odds Ratio (95% Cl)  pValue 
PAI-1 
Odds Ratio (95% Cl)  pValue 
Unadjusted Base 
Model 
0.215 (0.077, 0.594)     (0.003) 2.209 (1.460,3.344)    (<0.001) 
Adjusted for     
Recipient Age 0.202 (0.071, 0.571)    (0.003) 2.273 (1.490, 3.469)    (<0.001) 
Recipient Sex 0.209 (0.074, 0.591)    (0.003) 2.209 (1.459, 3.345)     (<0.001) 
Recipient Race 0.188 (0.064, 0.554)    (0.002) 2.177 (1.437, 3.296)     (<0.001) 
Recipient Diagnosis 0.166  (0.054,0.508)    (0.002) 2.191 (1.442, 3.330)     (<0.001) 
Recipient 
Transplant Type 
0.242 (0.083, 0.703)    (0.009) 2.084 (1.355, 3.207)     (<0.001) 
Recipient Ischemic 
Time 1 
0.224 (0.082, 0.615)    (0.004) 2.342 (1.505, 3.644)     (<0.001) 
Recipient Total 
Ischemic Time 
(total time= T1+T2) 
0.217 (0.054, 0.875)    (0.032) 2.511 (1.409, 4.475)     (0.002) 
Recipient Pre-Txp 
Oxygen 
0.181 (0.060,0.543)    (0.004) 2.169 (1.432, 3.283)    (<0.001) 
Cardio Pulmonary 
Bypass 
0.222 (0.072,0.683)     (0.009) 2.028 (1.308,3.144)      (0.002) 
Fresh Frozen 
Plasma (ml) w/in 
24hrs Post TXP 
0.186 (0.064, 0.545)     (0.002) 2.177 (1.440, 3.293)     (<0.001) 
Packed Red Blood 
Cells (ml) w/in 
24hrs Post TXP 
0.224 (0.077, 0.647)     (0.006) 2.177 (1.419, 3.340)     (<0.001) 
Platelets (ml) w/in 
24hrs Post TXP 
0.217 (0.073, 0.641)     (0.006) 2.065 (1.357, 3.140)      (<0.001) 
Pulmonary Artery 
Systolic Pressure at 
Transplantation 
0.131 (0.035, 0.499)     (0.003) 1.748 (1.076, 2.840)      (0.024) 
Pulmonary Artery 
Diastolic Pressure 
at Transplantation 
0.199 (0.059, 0.674)     (0.010) 1.830 (1.140, 2.939)      (0.012) 
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5. DISCUSSION 
The primary focus of this research is the risk of development of PGD (primary 
graft dysfunction) following lung transplant. The definition of PGD applied to the 
proposed research is the ISHLT Grade 3 PGD. Of the LTOG participants included in this 
research, 15 % (19 of 131) of participants met the outcome definition and as thus were 
considered the PGD group. Identification of 15% outcome cases within the sample 
population is consistent with previous research, 10-25%.1;2;9 
This research provides the first evidence of the role of biomarker concentration in 
PGD risk.  Specifically, we established the direct relationship of Protein C and PAI-1 
with the development of the outcome, Grade 3 PGD, in a prospective study of lung 
transplant patients. Biomarker levels immediate (within 11 hours), 24 (Day 1), 48 (Day 
2), and 72 hours (Day 3) post transplant between the PGD and Non-PGD groups differed 
significantly.   Within the PGD group, lower Protein C and higher PAI-1 levels were 
present over the course of the 72 hour period following transplant.  
The mean Protein C levels were consistently lower in the PGD group than in the 
Non-PGD group from immediate post up to 72 hours post transplant. Mean Protein C 
levels were also lower in the PGD group at pre-transplant, however further research 
standardizing the pre-transplant collection point is needed prior to being able to draw 
conclusions regarding the pre-transplant Protein C levels and levels post transplant.  
There was a difference in Protein C levels between the PGD and Non-PGD groups over 
the entire study period.  The PGD group experienced lower Protein C levels at most time 
points than the Non-PGD Group; however, the difference in Protein C levels between the 
PGD and Non-PGD groups were not statistically significant at the Day 1 (24 hour post 
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transplant) study time.  The first 24 hours post transplant could potentially be the turning 
point in determining which participants will go on to develop PGD and encounter longer 
lengths of hospital stays as well as increased mortality and morbidity. In future studies it 
may be beneficial to further investigate the Day 1 study interval and its association with 
the Protein C biomarker.  Participants with significantly lower levels of Protein C levels, 
as compared to the mean at Day 1, may be at greater risk for development of Grade 3 
PGD based on such low Protein C levels and the biomarkers association with the PGD 
outcome.   
Lower levels of Protein C could potentially be the result of an overactive immune 
system in response to ischemia reperfusion during removal from the donor and transplant 
to the recipient or once reperfused in recipient caused by a reaction to the cold storage 
conditions that the lungs are store in during this time period; ultimately, resulting in acute 
lung injury from the immune response, release or proinflammatory cytokines, decreased 
lung compliance and alveolar damage. 
Post transplant the mean PAI-1 levels of the PGD group was consistently higher 
than the Non-PGD group. PAI-1 levels between the two groups were statistically 
significantly at immediate and Day 1 post transplant. The PAI-1 levels between the two 
groups, PGD and Non-PGD groups, showed the most significant difference at the Day 1 
time interval, which is consistent with the hypothesis of this research that biomarker 
levels at the Day 1 study time are the most predictive of the PGD outcome.  The 
difference between the PAI-1 levels of the PGD and Non-PGD groups started to 
converge by Day 2.  As such, by Day 3 there was no longer a statistically significant 
difference in the PAI-1 levels between the PGD and Non-PGD groups. The release of 
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reactive oxygen species (ROS) in the transplanted lung following ischemia reperfusion 
could be a potential source of increased PAI-1 levels.  
 
 Post transplant both groups, PGD and Non-PGD, seemed to experience similar 
trends in biomarker levels, however the PGD group seemed to experience a more 
substantial loss of Protein C as well as a more substantial increase in PAI-1 levels.  PGD 
development could potentially be the result of the patient’s inability to recover from such 
steep changes in biomarker levels in response to ischemia reperfusion with the end result 
being activation of recipient neutrophils and T lymphocytes in reaction to the release of 
proinflammatory cytokines from the donor lung.12  Eventually leading to lung injury. 
The role of Protein C is to down regulate coagulation and limit clot formation to 
sites where it is required.  In PGD, lower levels of Protein C potentially allows for 
uncontrolled clot formation. Excessive clotting due to lower Protein C levels further leads 
to an imbalance in the coagulation cascade and potentially excessive fibrin accumulation.   
An increased level of the plasminogen activator inhibitor, PAI-1, was also 
characteristic of the PGD group.  PAI-1 inhibits fibrinolysis, which is the break down of 
fibrin clots formed during coagulation. The PGD group seemed to experience a major 
imbalance of the coagulation/fibrinolytic pathways as evidenced by the presence of lower 
levels of Protein C, which regulates clot formation and higher levels of PAI-1, which 
inhibits clot/fibrin degradation. In the PGD cases, fibrin clots are continually being 
formed unregulated (or regulated at a much lower rate) without being degraded due to the 
higher levels of PAI-1, which inhibits fibrinolysis.  Reduced inhibition of the coagulation 
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cascade coupled with decreased fibrinolytic activity seemed to be a major factor in PGD 
cases, possibly presenting as one of the major causes of acute lung injury in PGD.   
Preoperative (Prior) biomarker levels were also significantly different between the 
two groups, PGD and Non-PGD; however, there was no standardization of the pre-
transplant collection time interval for potential confounding factors.  Some pre-operative 
biomarker samples were obtained several months prior to transplant while others were 
obtained while participants were in the hospital just prior to the transplant procedure. 
Because we are uncertain of the collection conditions, the difference in plasma biomarker 
levels between the two groups at pre-transplant is possibly confounded by other factors 
administered to the participant as part of preparation for the transplant procedure which 
was not controlled in this research.  As such, because of a lack of standardization of the 
collection of specimens prior to transplant, the pre transplant time interval does not hold 
much validity in regards to this research. Additional studies with a standardized pre 
operative time point will need to be implemented prior to making any assumptions 
regarding the pre operative biomarker status of lung transplant participants and PGD.  
This is a significant condition to be applied in future studies. If pre-operative biomarker 
levels truly remain unchanged following transplant, recipient’s biomarker levels could 
potential be predictive of the outcome PGD and therefore serve as a measure for potential 
intervention prior to PGD onset. 
In this research study the actual levels of circulating protein C were measured.  
The Protein C receptors were not examined and it is unknown how they are affected by 
the transplant conditions.  The affect on zymogen conversion to active form could not be 
determined by just measuring the final state, or levels of actual protein present in 
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circulating blood, however, the finding of this research given the  Protein C levels 
between the PGD and Non-PGD lung transplant subjects was consistent with previous 
findings with ARDS, a similar syndrome.43;48 
For the PAI-1 analysis, the assay does not differentiate between activated or non-
activated PAI-1. Complications include the release of PAI-1 from the platelets giving 
older samples a higher PAI-1 level. Also, incorrect storage of the samples, as well as 
multiple freeze- thaw cycles can lead to potential loss of activity if not stored well. In 
addition, platelet transfusions can also affect the assay causing an increase in the 
sample’s PAI-1 levels; however samples were run in duplicate and against a new 
standard for each assay to guide against potential drift or non-reproducability. 
Biomarker levels were measured from plasma samples and not Bronchoalveolar 
lavage “BAL”. BAL is a diagnostic procedure of washing a sample of cells and 
secretions from the alveolar and bronchial airspaces. BAL fluid can be analyzed for local 
markers of lung injury, such as total cell numbers, differential cell count, total protein 
content and enzyme activities of lactate dehydrogenase (LDH) etc and sometimes is 
thought to be a better assessment of lung injury; however, in most cases of PGD the 
alveolar is damaged and as such this technique can not be performed in transplant 
patients. 
There has been insufficient evidence to make strong conclusions of association 
between PGD and many potential clinical risk factors, including advanced or young age, 
race, gender, previous chest surgery, liver dysfunction, renal dysfunction, left heart 
disease, blood transfusion, and single vs. bilateral transplantation. Previous research 
conducted by Whitson et al successfully identified lung transplant recipients at high risk 
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for severe PGD based on evaluation of donor and recipient risk factors, and concluded 
that such treatments aimed at reducing reperfusion injury might benefit this population of 
transplant patients.61  
The research conducted for this thesis provides additional evidence for potential 
clinical risk factors of PGD.   Assessing PGD vs. Non-PGD participants at the Day 1 (12-
36 hours post transplant) time interval showed that donor clinical risk variables, donor’s 
age, gender, race, history of smoking, and donor’s oxygen consumption levels, were not 
statistically different between the two groups.  This was very interesting because one 
would think that a donor’s history of smoking would have some sort of an effect on lung 
function and would have some impact or inference to PGD development, however this 
research supports otherwise.   The fact that donor’s characteristics were not statistically 
significant between the PGD and Non-PGD groups further supports the hypothesis of this 
research that recipient’s characteristics (such as recipients biomarker levels) are 
associated with the outcome, PGD .   
While no statistical significance in clinical risk factors between the two groups 
was determined for the donor variables assessed, this was also true in regards to 
recipients’ gender, ischemic time for the first lung, ischemic time for the second lung, 
bilateral transplant procedures, pre-transplant oxygen, and administration of fresh frozen 
plasma within the first 24 hrs post transplant.  Potential slight significant differences 
between the two groups, PGD and Non-PGD, were detected for age and race, p= 0.05 and 
0.05, however when race treated as a compounded categorical variable (Caucasian vs. 
non-Caucasian), there was no longer a statistically significant difference between the 
PGD and Non-PGD group in regards to race, p=0.09; it seems that the slight inference of 
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significance of both age and race is potentially false and due to the small sample size in 
each category. 
 A statistically significant difference between PGD and Non-PGD subjects was 
demonstrated for recipients’ diagnosis, procedure type, CPB, the volume of PRBC, 
platelets, PASP, and PADP.   Clinical risk factors were then assessed in a logistic model 
to determine if any were potential confounders of the relationship between biomarker 
levels and PGD.  
Previously confounders were shown to have an impact on lung transplant 
recipients and the outcome, PGD.  As such, this research employed  a logistic regression 
model to assess the relationship of confounder variables on biomarker levels and PGD in 
lung transplant recipients.   Each biomarker was assessed separately in a model with 
individual confounders. The model provided the odd ratios and probabilities of 
developing PGD based on the effect of potential confounder variables on biomarker 
levels.  The logistic regression model was utilized because it consists of a transformation 
that forces the prediction equation to predict values between 0 and 1.  It predicts the 
natural log of the odds for a subject to develop or not develop PGD.  A “-2log” or “score” 
was then used to interpret the independent variable’s significance based on a chi-square 
distribution of “p value” greater than 0.01.  Several categories of potential confounders 
were assessed including recipient’s clinical characteristics, pre-transplant state, and post 
transplant surgical variables. 
The increase in risk (odds ratio) for PGD associated with each 44% decrease in 
protein C level at Day 1 post transplant was 0.215 (p=0.003).  The increased risk for PGD 
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associated with each 88 ng/ml increase in PAI-1 levels at Day 1 post transplant was 2.209 
(p=<0.001). 
Upon further investigation of specific characteristics, it was determined that 
biomarker levels and the outcome (PGD) was independent of recipient’s age, sex, or race 
and this was true for both PAI-1 (p= <0.001, for all three) and Protein C (p=0.003, 0.003, 
and 0.002, respectively). Each variable had no effect on an individual’s odds of 
developing PGD and as such does not increase or decrease the risk of PGD.  
The participants’ pre-transplant state, more specifically a participant’s diagnosis 
and transplant procedure type (single lateral, bilateral, or heart and lung), when assessed 
in the PGD logistic model with biomarker levels, neither diagnosis nor transplant type 
were significant factors in regards to the relationship of biomarker levels and PGD. This 
was true for both Protein C (diagnose, p=0.002, transplant type, p=0.009) as well as PAI-
1, p=<0.001, for both diagnose and transplant type. Although their was a significant 
statistical difference in procedure type and diagnosis seen between the two groups, with 
PGD participants undergoing more bilateral procedures as well as diagnosed more often 
with  Idiopathic Pulmonary Fibrosis (IPF) and Primary Pulmonary Hypertension (PPH), 
than the  Non-PGD group; despite adjustments in the logistic model for both,  the 
relationship of biomarker levels and PGD was independent of recipient’s diagnosis 
and/or transplant type, the odds ratio for the base model remained unchanged despite 
adjustments for both and this was true for both Protein C and PAI-1. 
Prior to transplant, participants pre-oxygen level/utilization, was also not 
statistically significant for Protein C (p=0.004) or PAI-1 (p=<0.001). Once again, the 
odds ratio remained unchanged for both biomarkers when adjusted for Pre-oxygen, which 
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confirms that biomarker levels, both PAI-1 and Protein C relationship with PGD is 
independent of pre-transplant oxygen level/requirement, which was to be expected since 
there was no statistically significant difference in the requirement of pre-transplant 
oxygen between the two groups, PGD and Non-PGD (p=0.52).   
When adjusting for total ischemic time with PAI-1 and PGD levels, the odds ratio 
remained unchanged and as such  total ischemic time was an  insignificant factor 
(p=0.002) in regards to the relationship of  PAI-1  and PGD.  PAI-1 levels and the 
outcome PGD were independent of total ischemic time, and the same was true for Protein 
C, (p=0.032). One would expect that the total ischemic time would have some affect on 
biomarker levels and PGD because of the imbalance of the coagulation and fibrinolytic 
systems in PGD. 
The relationship of biomarker levels and PGD was independent of blood products 
administered within the first 24 hours post transplant, this included administration of 
fresh frozen plasma, platelets, or packed red blood cells. All three factors, fresh frozen 
plasma, platelets, and packed red blood cells were insignificant factors in the relationship 
of biomarker levels and PGD.  Although there was a statistically significant difference in 
the volume of several of the blood products administered to PGD as opposed to  Non-
PGD subjects, such as PRBC (1,205 vs 393 mls, respectively,) and platelets (287 vs 76 
mls, respectively,),  the odds ratio remained unchanged despite adjustments for each, 
which confirmed that the relationship of biomarker levels and PGD is independent of the 
administration of  all blood products administered in the first 24 hours post transplant. 
Both biomarkers, Protein C and PAI-1 were independent of Pulmonary Arterial 
Diastolic Pressure (PADP), p=0.010 and 0.012, respectively; as well as independent of 
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Pulmonary Arterial Systolic Pressure (PASP), Protein C and PGD (p=0.003); PAI-1 ( 
p=0.024).   
Both Protein C and PAI-1 levels in regards to PGD were independent of CPB.  
The base models of both biomarkers were not significantly effected and the odds ratio of 
both remained unchanged despite adjustments for CPB. This is consistent with previous 
research in regard to surgical technique-related risk factors, studies adjusting for PPH, 
which suggested that cardiopulmonary bypass was not a risk factor for PGD.13 
In conclusion, the relationship of both biomarkers,Protein C and PAI-1, with PGD 
was independent of all potential confounders. 
 
PGD is very important to transplant research because it is a major cause of 
morbidity following lung transplant. PGD is a unique model to study lung injury because 
it provides a closed sample population with known reasons of syndrome that can be 
monitored from onset to recovery, or death. The coagulation and fibrinolytic pathways, 
both have been implicated in other acute lung injury and there fore are also suspect in 
PGD. Additional experimental treatments are needed to address this outcome, see Table 
15: Treatments for PGD After Development, Hoffman, 2007.  While this research 
provides additional support for administering Protein C (activated protein C “Xigris) as 
therapy to at risk or PGD patients  additional validation studies will need to be conducted 
prior to fully supporting predictive measures of  biomarkers.   Additional research in 
human models have supported other interesting pathophysiological roles in the prediction 
of PGD such as human studies of IL-8 levels in BAL,27;79 RNA ratios,80 and vascular 
endothelial growth factor62  
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Table 15: Treatments for PGD After Development 
Level of 
support 
Principle Intervention 
Consensus General PGD 
care 
General supportive intensive care principles 
Lung protective (low tidal volume) mechanical 
ventilation 
Conservative crystalloid fluid management 
Maintain hematocrit (25% - 30%) 
Maintain coagulation parameters 
 Hypoxemia and 
/ or severe 
pulmonary 
hypertension 
Consider nitric oxide 
Consider Prostacyclin 
 Life-threatening 
PGD not 
responding to 
therapy 
Consider extracorporeal membrane oxygenation 
   (if within 7 days post-transplantation) 
Consider re-transplantation (if without other end-organ 
damage) 
Experimental  ??????? 
 
 
The results of this research will help 1) the understanding of the causes of PGD; 
2) the effect of biomarker levels in development of PGD; 3) identifying the various stages 
of PGD and how each stage is influenced by relevant biomarker levels; 4) evidence to 
suggest further laboratory investigations in the Coagulation and Fibrinolytic pathways; 
and 5) the ability to prevent and/or control PGD in lung transplant recipients. Promising 
biomarkers discovered in this protocol may serve as targets for further laboratory 
research into the mechanisms of the association biomarker levels and PGD. An example 
would be cell-based studies of the effect of higher or lower levels of these biomarkers 
have on surrounding systems. In addition, identification of high risk variables from this 
study could be very useful for identification of high risk combinations of donors and 
recipients in clinical transplantation. With improved identification of patients at risk for 
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developing PGD and better understanding of why they are at risk and the level of disease 
state following transplant, future trials could be performed that match specific strategies 
with specific patient groups based on these biomarkers. Given that donors and recipients 
are available prior to the procedure, rapid screening for targeted prevention or early 
treatments trials could be attempted. In addition this research also provide additional 
support for possible therapeutic treatments of PGD, such as administration of Protein C 
(activated protein C “Xigris) to at risk or PGD patients to potentially decrease mortalities 
and increase long term survival of at risk and PGD patients. Also of importance this 
research provided the first evidence associating enhanced coagulation and impaired 
fibrinolysis with PGD in the human lung transplant population. 
 
6. CONCLUSION  
As hypothesized a proportion of the sample population (15%) were identified as 
having the outcome, PGD. Both Pai-1 and Protein C levels differed over time in the 
outcome vs non outcome group. The PGD group has consistently significant higher PAI-
1 levels and lower Protein C levels. The levels of Protein C on Immediate Post Transplant 
and PAI-1 at Day 1 was the most significant. Donor characteristics and potential risk 
factors proved to be less significant as compared to recipient clinical risk and post 
transplant factors. When assessed in a logistic regression model, several recipient factors 
proved to have a significant effect on both PAI-1 and Protein C levels and the outcome, 
PGD. 
In conclusion, lower levels of Protein C and higher levels of PAI -1 are associated 
with the outcome, PGD. This research provided additional evidence that recipient 
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characteristics, more specifically, recipient’s diagnosis, procedure type, CPB, post 
transplant PASP, post transplant PADP, as well as administration of PRBC, FFP, and 
platelets within the first 24hrs post transplant are all characteristics of PGD subjects.  In 
regards to potential confounders, based on the fact that the odds ratio did not change 
much between the unadjusted and adjusted models, the observed association between 
PGD and biomarker levels, both Protein C and PAI-1, was significant and it independent 
all potential confounder variables assessed.  Biomarker levels are associated (or an 
important risk factor) with PGD because the 95% CI does not include 1.0, which is 
consistent with the small p-values and this is true for BOTH the unadjusted and adjusted 
models.  
This research accomplished its initial goals, which were to provide insight into the 
mechanisms of progression to PGD, aid in potential characterization of PGD based on 
donor and recipient characteristics, identify potential confounder variables in regards to 
biomarker levels and PGD, as well as to provide justification for novel therapeutics 
aimed at preventing PGD prior to full onset or death.  
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